N/A N=10 EndoBarrier in Obese Subjects With Type 2 Diabetes Mellitus
Type 2 Diabetes · Obesity
Primary: Changes in Insulin Sensitivity — 0.97 milligram per kilogram per minute — p=0.001
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
N/A N=40 Virtual Reality in the Operating Room
Anesthesia, Intravenous · Pain, Postoperative · Delayed Recovery From Anesthesia
Primary: Intraoperative Propofol Dose — 0.14; 0.00 mg/kg/min
N/A N=40 Use of Stable Airway Management Device in Monitored Anesthesia Care
Anesthesia
Primary: Total Apneic Events /Total Number Requiring Airway Manipulation — 2; 1 Number of airway manipulations
N/A N=200 Early Progesterone Cessation After in Vitro Fertilization
Pregnant Women
Primary: Number of Bleeding Episodes — 8; 8 Episodes of bleeding
Phase 3 N=938 A Study of Tirzepatide (LY3298176) in Participants With Type 2 Diabetes Who Have Obesity or Are Overweight
Type 2 Diabetes · Overweight · Obesity
Primary: Percent Change From Baseline in Body Weight — -3.3; -13.4; -15.7 percent change — p=<0.001
N/A N=149 SpotCheck: Comparison of Enhanced Telemedicine Versus In-person Evaluation for the Diagnosis of Skin Cancer
Skin Cancer
Primary: Accuracy of Skin Cancer Diagnosis: In-Person Assessment — 93 percentage of skin lesions
N/A N=14 Passive Tactile Stimulation for Stroke Rehabilitation
Stroke · Stroke, Ischemic · Stroke Hemorrhagic
Primary: Change in Modified Ashworth at 12 Weeks — 1.1 units on a scale — p=0.00025
Phase 1 N=8 Phase 1b Study PVSRIPO for Recurrent Malignant Glioma in Children
Malignant Glioma · Anaplastic Astrocytoma · Anaplastic Oligoastrocytoma
Primary: Percentage of Participants With Unacceptable Toxicity — 0 percentage of participants
Phase 1 N=17 Blinatumomab in Combination With AMG 404 for the Treatment of Adults With Relapsed or Refractory B Cell Precursor ALL
Acute Lymphoblastic Leukemia
Primary: Number of Participants Who Experienced Dose-Limiting Toxicities (DLTs) — 0; 0 Participants
Phase 2 N=57 SARS-CoV-2-Neutralizing Monoclonal COVID-19 Antibody DZIF-10c by Infusion
SARS-CoV-2 Infection
Primary: Proportion of Patients With Any AE Within 7 d of Study Drug Infusion — 2; 1; 0; 0 Participants
Phase 2 N=12 LCI-HEM-MYE-CRD-004 (MMRC-073 CARJAK): Study of CRD for Carfilzomib-Refractory Multiple Myeloma
Multiple Myeloma
Primary: Dose Limiting Toxicity (DLT) — 0; 0; 1 participants
N/A N=51 Study to Evaluate Clinical Real World Outcomes of Lorlatinib After Alectinib in ALK-Positive NSCLC Japanese Patients
ALK-positive Non-small-cell Lung Cancer
Primary: Age at Start of Lorlatinib Treatment — 57.7; 58.1 Years
N/A N=26 An Exploratory Prospective Trial of Rescue Acupuncture for the Treatment of Acute Migraine
Migraine
Primary: Change of Migraine Headache Pain — 16; 2 Participants
Phase 4 N=17 Cold Atmospheric Plasma Device for Pediatric Molluscum and Verruca
Verruca Vulgaris · Molluscum Contagiosum Skin Infection
Primary: Numbers of Lesions With no Response — 8; 9 lesions — p=0.534
Phase 3 N=100 The Use of Methylsulfonylmethane (MSM) in the Treatment of Low Back Pain
Low Back Pain
Primary: Pain Level — 3.4; 3.7; 2.8; 2.9 score on a scale